

Ronan Roussel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8278833/publications.pdf>

Version: 2024-02-01

141
papers

6,887
citations

117571

34
h-index

71651

76
g-index

149
all docs

149
docs citations

149
times ranked

14616
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014, 46, 1173-1186.	9.4	1,818
2	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. <i>Diabetologia</i> , 2020, 63, 1500-1515.	2.9	638
3	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. <i>Cell Metabolism</i> , 2018, 28, 737-749.e4.	7.2	356
4	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>. <i>Archives of Internal Medicine</i> , 2010, 170, 1892.	4.3	319
5	Patient-level meta-analysis of the <sc>EDITION</sc> 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 859-867.	2.2	207
6	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <i>Diabetes Care</i> , 2018, 41, 2147-2154.	4.3	159
7	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703.	4.3	147
8	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. <i>Diabetologia</i> , 2021, 64, 778-794.	2.9	120
9	Comparison Between Copeptin and Vasopressin in a Population From the Community and in People With Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4656-4663.	1.8	110
10	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. <i>Cardiovascular Diabetology</i> , 2018, 17, 138.	2.7	104
11	Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F2-F23.	1.3	88
12	Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 15-21.	1.4	81
13	A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The Tj ETQq1 1 0.7ĺ rgB1/Overlo		
14	Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria. <i>Diabetes Care</i> , 2013, 36, 3639-3645.	4.3	73
15	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <sc>U/mL</sc> vs glargine 100 <sc>U/mL</sc>: 1-year patient-level meta-analysis of the <sc>EDITION</sc> clinical studies in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 541-548.	2.2	69
16	Prognostic Value of the Insertion/Deletion Polymorphism of the <i>ACE</i> Gene in Type 2 Diabetic Subjects. <i>Diabetes Care</i> , 2008, 31, 1847-1852.	4.3	66
17	Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort. <i>Diabetes Care</i> , 2014, 37, 1425-1431.	4.3	65
18	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. <i>Diabetes and Metabolism</i> , 2021, 47, 101216.	1.4	65

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2148-2158.	2.2	59
20	Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. <i>Diabetes Care</i> , 2021, 44, 1368-1376.	4.3	59
21	Plasma Copeptin, <i>AVP</i> Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2432-2439.	1.8	58
22	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: perspective on glucose-lowering interventions. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 238-244.	2.2	58
23	Different Patterns of Insulin Resistance in Relatives of Type 1 Diabetic Patients With Retinopathy or Nephropathy: The Genesis France-Belgium Study. <i>Diabetes Care</i> , 2004, 27, 2661-2668.	4.3	55
24	Loss-of-function mutations in <i>MRAP2</i> are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. <i>Nature Medicine</i> , 2019, 25, 1733-1738.	15.2	54
25	Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2288-2295.	4.3	51
26	Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. <i>Diabetes Therapy</i> , 2019, 10, 617-633.	1.2	50
27	Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. <i>European Heart Journal</i> , 2015, 36, 2716-2728.	1.0	48
28	<i>GPS2</i> Deficiency Triggers Maladaptive White Adipose Tissue Expansion in Obesity via <i>HIF1A</i> Activation. <i>Cell Reports</i> , 2018, 24, 2957-2971.e6.	2.9	48
29	Plasma extracellular superoxide dismutase concentration, allelic variations in the <i>SOD3</i> gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 845.	2.7	47
30	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. <i>Diabetes Care</i> , 2018, 41, 1672-1680.	4.3	44
31	Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study. <i>American Journal of Nephrology</i> , 2015, 42, 107-114.	1.4	43
32	Association of Circulating Biomarkers (Adrenomedullin, <i>TNFR1</i> , and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. <i>Diabetes Care</i> , 2017, 40, 367-374.	4.3	43
33	Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. <i>European Journal of Nutrition</i> , 2019, 58, 315-324.	1.8	43
34	Pathogenic variants in actionable <i>MODY</i> genes are associated with type 2 diabetes. <i>Nature Metabolism</i> , 2020, 2, 1126-1134.	5.1	43
35	Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1259-1266.	4.3	38
36	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. <i>Heart</i> , 2017, 103, 1339-1346.	1.2	38

#	ARTICLE	IF	CITATIONS
37	The expression of genes in top obesity-associated loci is enriched in insula and substantia nigra brain regions involved in addiction and reward. <i>International Journal of Obesity</i> , 2020, 44, 539-543.	1.6	38
38	Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 12-19.	1.5	37
39	Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. <i>Diabetologia</i> , 2019, 62, 939-947.	2.9	36
40	Stay-at-Home Orders During the COVID-19 Pandemic, an Opportunity to Improve Glucose Control Through Behavioral Changes in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 839-843.	4.3	36
41	Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 110.	2.7	35
42	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. <i>Diabetes Care</i> , 2020, 43, e174-e177.	4.3	35
43	Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2371-2380.	1.8	35
44	Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM. <i>Diabetes and Metabolism</i> , 2018, 44, 402-409.	1.4	33
45	Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1162-1172.	2.2	33
46	Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population. <i>JCI Insight</i> , 2018, 3, .	2.3	32
47	Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e96916.	1.1	31
48	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Advances in Therapy</i> , 2015, 32, 1029-1064.	1.3	30
49	ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients. <i>Diabetologia</i> , 2016, 59, 2321-2330.	2.9	30
50	Contribution of the low-frequency, loss-of-function p.R270H mutation in <i>FFAR4</i> (<i>GPR120</i>) to increased fasting plasma glucose levels. <i>Journal of Medical Genetics</i> , 2015, 52, 595-598.	1.5	29
51	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 40-44.	1.2	28
52	Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. <i>Diabetes Therapy</i> , 2016, 7, 537-549.	1.2	28
53	Plasma concentrations of 8-hydroxy-2'-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 977-984.	2.9	28
54	Relationship between cardiac microvascular dysfunction measured with ⁸² Rubidium-PET and albuminuria in patients with diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018, 17, 11.	2.7	28

#	ARTICLE	IF	CITATIONS
55	Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 220, 137-142.	0.8	24
56	Urinary lysophospholipids are increased in diabetic patients with nephropathy. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1103-1108.	1.2	24
57	COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. <i>Diabetes and Metabolism</i> , 2021, 47, 101162.	1.4	22
58	Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients. <i>Diabetes</i> , 2005, 54, 2961-2967.	0.3	21
59	Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 5.	2.7	20
60	Kinin Receptor Agonism Restores Hindlimb Postischemic Neovascularization Capacity in Diabetic Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 218-226.	1.3	19
61	Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade. <i>Clinical Science</i> , 2016, 130, 45-56.	1.8	19
62	Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT Study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 781-790.	2.2	19
63	Exposure to persistent organic pollutants and the risk of type 2 diabetes: a case-cohort study. <i>Diabetes and Metabolism</i> , 2021, 47, 101234.	1.4	19
64	Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling. <i>Molecular Metabolism</i> , 2016, 5, 918-925.	3.0	18
65	Vasopressin and diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 311-318.	1.0	18
66	The vasopressin system: new insights for patients with kidney diseases. <i>Journal of Internal Medicine</i> , 2017, 282, 310-321.	2.7	17
67	Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 943-953.	2.2	17
68	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications. <i>Circulation</i> , 2016, 134, 571-573.	1.6	16
69	Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. <i>Journal of Medical Economics</i> , 2016, 19, 131-144.	1.0	16
70	Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 929-932.	1.2	16
71	Severe Chronic Kidney Disease Is Associated with a Lower Efficiency of Bariatric Surgery. <i>Obesity Surgery</i> , 2019, 29, 1514-1520.	1.1	16
72	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3364-e3368.	1.8	16

#	ARTICLE	IF	CITATIONS
73	Beta-cell function is associated with carotid intima-media thickness independently of insulin resistance in healthy individuals. <i>Journal of Hypertension</i> , 2016, 34, 685-691.	0.3	15
74	Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1289-1292.	2.2	15
75	New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans. <i>Molecular Metabolism</i> , 2019, 29, 182-196.	3.0	15
76	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 2290-2297.	4.3	15
77	Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort. <i>Diabetes and Metabolism</i> , 2021, 47, 101222.	1.4	15
78	The COVID-19 lockdown as an opportunity to change lifestyle and body weight in people with overweight/obesity and diabetes: Results from the national French COVIDIAB cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2605-2611.	1.1	15
79	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. <i>Diabetologia</i> , 2013, 56, 2733-2742.	2.9	14
80	Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. <i>Free Radical Biology and Medicine</i> , 2015, 86, 16-24.	1.3	14
81	Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β -cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. <i>International Journal of Epidemiology</i> , 2015, 44, 1927-1940.	0.9	14
82	T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population. <i>Diabetes and Metabolism</i> , 2017, 43, 33-39.	1.4	14
83	Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2162-2169.	4.3	14
84	Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 755-768.	1.4	14
85	Disagreement between capillary blood glucose and flash glucose monitoring sensor can lead to inadequate treatment adjustments during pregnancy. <i>Diabetes and Metabolism</i> , 2020, 46, 158-163.	1.4	14
86	Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1172-1181.	0.6	13
87	SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 203-209.	1.4	13
88	SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. <i>Cardiovascular Diabetology</i> , 2021, 20, 107.	2.7	13
89	Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 611-618.	2.4	13
90	Plasma Adrenomedullin and Allelic Variation in the <i>ADM</i> Gene and Kidney Disease in People With Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 3262-3272.	0.3	12

#	ARTICLE	IF	CITATIONS
91	Urinary Sodium Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality in a Type 2 Diabetes Cohort Population. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-10.	1.0	12
92	Real-world outcomes of treatment with insulin glargine 300â€‰U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020, 36, 571-581.	0.9	12
93	Insulin glargine 300â€‰U/mL and insulin degludec: A review of the current evidence comparing these two secondâ€‰generation basal insulin analogues. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3329.	1.7	12
94	Plasma Apelin and Risk of Type 2 Diabetes in a Cohort From the Community. <i>Diabetes Care</i> , 2020, 43, e15-e16.	4.3	12
95	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. <i>Diabetologia</i> , 2021, 64, 668-680.	2.9	12
96	Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases. <i>PLoS ONE</i> , 2015, 10, e0137733.	1.1	12
97	ABCG8 polymorphisms and renal disease in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 713-719.	1.5	11
98	Leukocyte Telomere Length, DNA Oxidation, and Risk of Lower-Extremity Amputation in Patients With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 828-834.	4.3	11
99	Gene Polymorphisms of FABP2, ADIPOQ and ANP and Risk of Hypertriglyceridemia and Metabolic Syndrome in Afro-Caribbeans. <i>PLoS ONE</i> , 2016, 11, e0163421.	1.1	10
100	Longitudinal association of antidepressant medication use with metabolic syndrome: Results of a 9-year follow-up of the D.E.S.I.R. cohort study. <i>Psychoneuroendocrinology</i> , 2016, 74, 34-45.	1.3	10
101	Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2751-2759.	4.3	10
102	Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program. <i>Diabetes Care</i> , 2020, 43, e43-e44.	4.3	10
103	Is the Consensual Threshold for Defining High Glucose Variability Implementable in Clinical Practice?. <i>Diabetes Care</i> , 2021, 44, 1722-1725.	4.3	10
104	Interaction between GPR120 p.R270H loss-of-function variant and dietary fat intake on incident type 2 diabetes risk in the D.E.S.I.R. study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 931-936.	1.1	9
105	Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1731-1738.	0.4	9
106	Adipocyte Reprogramming by the Transcriptional Coregulator GPS2 Impacts Beta Cell Insulin Secretion. <i>Cell Reports</i> , 2020, 32, 108141.	2.9	9
107	The evaluation of offâ€‰loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale. <i>Journal of Foot and Ankle Research</i> , 2016, 9, 34.	0.7	8
108	Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twiceâ€‰daily basal insulin to onceâ€‰daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2) Tj ETQq020 rgBT /Overlock 1		

#	ARTICLE	IF	CITATIONS
109	History of bariatric surgery and COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Obesity</i> , 2022, 30, 599-605.	1.5	7
110	<i>ACE</i> I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1377-1384.	4.3	6
111	Le diabète et l'obésité, rôle des maladies héréditaires d'un passé de chasseurs-cueilleurs ? <i>Diabetologia Notes De Lecture</i> , 2009, 1, 35-36.	0.0	5
112	Sex hormone levels are not associated with progression of renal disease in male patients with T2DM. <i>Diabetes and Metabolism</i> , 2017, 43, 140-145.	1.4	5
113	No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 494-497.	1.4	5
114	Reliability and Safety of Bedside Blind Bone Biopsy Performed by a Diabetologist for the Diagnosis and Treatment of Diabetic Foot Osteomyelitis. <i>Diabetes Care</i> , 2021, 44, 2480-2486.	4.3	5
115	Le traitement du diabète de type 2 en France est dynamique plutôt qu'inerte : analyse des prescriptions de 847 122 patients. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 346-352.	0.1	4
116	Bariatric surgery and chronic kidney disease: much hope, but proof is still awaited. <i>International Journal of Obesity</i> , 2018, 42, 1532-1533.	1.6	4
117	Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, JANI P et al [letter]. <i>Diabetologia</i> , 2020, 63, 2491-2494.	2.9	4
118	Identification of Key Regions Mediating Human Melatonin Type 1 Receptor Functional Selectivity Revealed by Natural Variants. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1614-1627.	2.5	4
119	Dairy consumption is associated with lower plasma dihydroceramides in women from the D.E.S.I.R. cohort. <i>Diabetes and Metabolism</i> , 2020, 46, 144-149.	1.4	3
120	Comparison of a new versus standard removable offloading device in patients with neuropathic diabetic foot ulcers: a French national, multicentre, open-label randomized, controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000954.	1.2	3
121	Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 1861-1872.	1.2	3
122	Association Between the <i>ACE</i> Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 407-415.	4.3	3
123	Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 392-394.	1.4	2
124	T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1987-1993.	0.4	2
125	Association of impaired renal function with venous thrombosis: A genetic risk score approach. <i>Thrombosis Research</i> , 2017, 158, 102-107.	0.8	2
126	Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, 71.	2.7	2

#	ARTICLE	IF	CITATIONS
127	Le salsalate, un dérivé de l'aspirine, pourrait être un anti-diabétique, en agissant plutôt sur l'insulino-sécrétion que l'insulino-sensibilité. Diabetologia Notes De Lecture, 2009, 1, 1-2.	0.0	1
128	Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial. Diabetes and Metabolism, 2017, 43, 187-190.	1.4	1
129	Agonistes du récepteur du GLP-1 : puissance ou transcendance ? Des outils pour contrôler glycémie et pression artérielle. Medecine Des Maladies Metaboliques, 2018, 12, 31-35.	0.1	1
130	Associations of fats and carbohydrates with cardiovascular disease and mortality—PURE and simple?. Lancet, The, 2018, 391, 1680.	6.3	1
131	Relationship between renal capacity to reabsorb glucose and renal status in patients with diabetes. Diabetes and Metabolism, 2020, 46, 488-495.	1.4	1
132	Une vision de l'organisation moderne d'un service hospitalier de diabétologie. Medecine Des Maladies Metaboliques, 2021, 15, 585-590.	0.1	1
133	Mesure de l'accumulation cutanée des produits avancés de la glycation: un progrès pour la prédiction du risque cardiovasculaire ?. Diabetologia Notes De Lecture, 2009, 1, 31-32.	0.0	0
134	La micro-angiopathie: plus de prévention possible après quelques années de diabète de type 2 ?. Diabetologia Notes De Lecture, 2009, 1, 61-62.	0.0	0
135	Contrôle intensif de la glycémie: moins d'infarctus du myocarde. Diabetologia Notes De Lecture, 2010, 2, 15-16.	0.0	0
136	Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!. Diabetes and Metabolism, 2010, 36, 86-87.	1.4	0
137	FRI0546...Pituitary-adrenal function after prolonged glucocorticoid therapy in systemic disorders. Annals of the Rheumatic Diseases, 2013, 72, A559.3-A560.	0.5	0
138	Letter by Potier and Roussel Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes". Circulation, 2019, 139, 303-304.	1.6	0
139	Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: the SFDT1 study. Diabetes and Metabolism, 2021, 48, 101306.	1.4	0
140	Hypertriglyceridemia in the MESA Study. JAMA Cardiology, 2022, , .	3.0	0
141	Epigenetic changes associated with hyperglycaemia exposure in the longitudinal D.E.S.I.R. cohort. Diabetes and Metabolism, 2022, 48, 101347.	1.4	0